TABLE 1

Characteristics of the Included Studies

Garin et al, 20067Pennesi et al, 20089Montini et al, 20088Craig et al, 200910Brandström et al, 201111Hoberman, et al 20143Hari et al, 201512
Total enrolled patients21810033857620360793
No. of patients with a complete DMSA evaluation21810029515113644780
Boy/girl40/17852/48104/234207/36975/12849/55862/31
Age, y≤18≤2.5≤7≤18≤2≤6≤12
VUR grade0–IIIII–IV0–III0–VIII–IVI–IVI–IV
Previous UTIYesYesYesYesYesYesYes
Study designOpen-labelOpen-labelOpen-labelPlaceboOpen-labelPlaceboPlacebo
Type of prophylaxisTMP/SMZTMP/SMZTMP/SMZ or AmoxiclavulanateTMP/SMZTrimethoprimTMP/SMZTMP/SMZ
Timing of follow-up DMSA, y121121 and 21
  • TMP/SMZ, Trimethoprim/Sulfamethoxazole.